Login to Your Account



Pharma: Clinic Roundup


Monday, October 7, 2013
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, disclosed results of a Phase I/II study of its intramuscular bivalent (GI/GII) norovirus vaccine candidate in healthy adult volunteers who were challenged with the most commonly occurring norovirus (genotype GII.4) that causes gastroenteritis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription